EMD-20863

Single-particle
3.87 Å
EMD-20863 Deposition: 26/10/2019
Map released: 29/04/2020
Last modified: 13/11/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-20863

CryoEM structure of human alpha4beta2 nicotinic acetylcholine receptor with varenicline in complex with anti-BRIL synthetic antibody BAK5

EMD-20863

Single-particle
3.87 Å
EMD-20863 Deposition: 26/10/2019
Map released: 29/04/2020
Last modified: 13/11/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: human alpha4beta2 nicotinic acetylcholine receptor in complex fab fragments and bound to varenicline
Fitted models: 6usf (Avg. Q-score: 0.394)

Deposition Authors: Alvarez FJD, Mukherjee S, Han S
Synthetic antibodies against BRIL as universal fiducial marks for single-particle cryoEM structure determination of membrane proteins.
PUBMED: 32221310
DOI: doi:10.1038/s41467-020-15363-0
ISSN: 2041-1723
Abstract:
We propose the concept of universal fiducials based on a set of pre-made semi-synthetic antibodies (sABs) generated by customized phage display selections against the fusion protein BRIL, an engineered variant of apocytochrome b562a. These sABs can bind to BRIL fused either into the loops or termini of different GPCRs, ion channels, receptors and transporters without disrupting their structure. A crystal structure of BRIL in complex with an affinity-matured sAB (BAG2) that bound to all systems tested delineates the footprint of interaction. Negative stain and cryoEM data of several examples of BRIL-membrane protein chimera highlight the effectiveness of the sABs as universal fiducial marks. Taken together with a cryoEM structure of sAB bound human nicotinic acetylcholine receptor, this work demonstrates that these anti-BRIL sABs can greatly enhance the particle properties leading to improved cryoEM outcomes, especially for challenging membrane proteins.